Prymnesins, produced by the haptophyte Prymnesium parvum, are considered responsible for fish kills when this species blooms. Although their toxic mechanism is not fully understood, membrane disruptive properties have been ascribed to A-type prymnesins. Currently it is suggested that pore-formation is the underlying cause of cell disruption. Here the hypothesis that A-, B-, and C-type prymnesins interact with sterols in order to create pores was tested. Prymnesin mixtures containing various analogs of the same type were applied in hemolysis and cytotoxicity assays using Atlantic salmon Salmo salar erythrocytes or rainbow trout RTgill-W1 cells. The hemolytic potency of the prymnesin types reflected their cytotoxic potential, with approximate concentrations reaching 50 % hemolysis (HC50) of 4 nM (A-type), 54 nM (C-type), and 600 nM (B-type). Variabilities in prymnesin profiles were shown to influence potency. Prymnesin-A (3 Cl) + 2 pentose + hexose was likely responsible for the strong toxicity of A-type samples. Co-incubation with cholesterol and epi-cholesterol pre-hemolysis reduced the potential by about 50 % irrespective of sterol concentration, suggesting interactions with sterols. However, this effect was not observed in RTgill-W1 toxicity. Treatment of RTgill-W1 cells with 10 µM lovastatin or 10 µM methyl-β-cyclodextrin-cholesterol modified cholesterol levels by 20-30 %. Regardless, prymnesin cytotoxicity remained unaltered in the modified cells. SPR data showed that B-type prymnesins likely bound with a single exponential decay while A-types seemed to have a more complex binding. Overall, interaction with cholesterol appeared to play only a partial role in the cytotoxic mechanism of pore-formation. It is suggested that prymnesins initially interact with cholesterol and stabilize pores through a subsequent, still unknown mechanism possibly including other membrane lipids or proteins.
Keywords: Cholesterol; Cytotoxicity; Hemolysis; Prymnesium parvum; RTgill-W1; Toxin mixture.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.